These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 37081961)

  • 1. Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
    Li D; Gou J; Zhu J; Zhang T; Liu F; Zhang D; Dai L; Li W; Liu Q; Qin C; Du Q; Liu S
    Front Pharmacol; 2023; 14():1117391. PubMed ID: 37081961
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
    Li D; Chai S; Wang H; Dong J; Qin C; Du D; Wang Y; Du Q; Liu S
    Front Pharmacol; 2023; 14():1259611. PubMed ID: 38186652
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database.
    Li D; Wang H; Qin C; Du D; Wang Y; Du Q; Liu S
    Clin Pharmacol Ther; 2024 Mar; 115(3):535-544. PubMed ID: 38069538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe cutaneous adverse reactions due to antibiotics therapy: a pharmacovigilance analysis of FDA adverse event reporting system events.
    Zhou L; Yang J; Xiao M; Shan H; Liu M; Lu Y; Zou Y; Wu B
    Expert Opin Drug Saf; 2023 Nov; ():1-8. PubMed ID: 37937960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A real-world pharmacovigilance study of severe cutaneous adverse reactions associated with antiepileptic drug combination therapy: data mining of FDA adverse event reporting system.
    Wei C; Zhang J; Yin W; Jiang A; Liu Y; Wu B
    Expert Opin Drug Saf; 2023; 22(6):509-515. PubMed ID: 36373417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of Individual Case Safety Reports of Severe Cutaneous Adverse Reactions in Korea.
    Kang MG; Sohn KH; Kang DY; Park HK; Yang MS; Lee JY; Kang HR
    Yonsei Med J; 2019 Feb; 60(2):208-215. PubMed ID: 30666843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Collaboration in pharmacovigilance: lamotrigine and fatal severe cutaneous adverse reactions - a review of spontaneous reports.
    Brickel N; Shaikh H; Kirkham A; Davies G; Chalker M; Yoshida P
    Ther Clin Risk Manag; 2017; 13():897-903. PubMed ID: 28790833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database.
    Hosohata K; Inada A; Oyama S; Niinomi I; Wakabayashi T; Iwanaga K
    Clin Drug Investig; 2019 Apr; 39(4):363-368. PubMed ID: 30689189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pharmacovigilance Study of Adverse Drug Reactions Reported for Cardiovascular Disease Medications Approved Between 2012 and 2017 in the United States Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Patel NM; Stottlemyer BA; Gray MP; Boyce RD; Kane-Gill SL
    Cardiovasc Drugs Ther; 2022 Apr; 36(2):309-322. PubMed ID: 33599896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Data in Pharmacovigilance Database Provides a New Perspective for Understanding the Risk of
    Li D; Song Y; Bai Z; Xi X; Liu F; Zhang Y; Qin C; Du D; Du Q; Liu S
    Antibiotics (Basel); 2023 Jun; 12(7):. PubMed ID: 37508205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of severe cutaneous adverse reactions (SCARs) in Taiwan drug-injury relief system: 18-year results.
    Huang PW; Chiou MH; Chien MY; Chen WW; Chu CY
    J Formos Med Assoc; 2022 Aug; 121(8):1397-1405. PubMed ID: 34674904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
    Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
    Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis.
    Liu Y; Liu Y; Fan R; Kehriman N; Zhang X; Zhao B; Huang L
    Eur J Med Res; 2023 Feb; 28(1):95. PubMed ID: 36829251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System.
    Barcelos FC; de Matos GC; da Silva MJS; da Silva FAB; Lima EDC
    Front Pharmacol; 2019; 10():498. PubMed ID: 31139083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An experimental investigation of masking in the US FDA adverse event reporting system database.
    Wang HW; Hochberg AM; Pearson RK; Hauben M
    Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
    Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
    Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is pitolisant safe for clinical use? A retrospective pharmacovigilance study focus on the post-marketing safety.
    Jiang C; Qian J; Jiang X; Zhang S; Zheng J; Wang H
    Pharmacol Res Perspect; 2024 Feb; 12(1):e1161. PubMed ID: 38174838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
    Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
    Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.